Dr. Vaibhav Choudhary

AREA(S) OF INTEREST:

Precision Oncology, Personalised Cancer care, Systemic Treatment of all forms of Cancer, Managing relapsed and refractory stage 4 cancer, Clinical Trial, Translational Research

PROCEDURES PERFORMED:

Cancer Immunotherapy, Targeted Therapy, Chemotherapy for all kinds of Cancers Neoadjuvant, Adjuvant, Concurrent and Palliative therapy including Chemotherapy administration and supportive care

NAME OF INSTITUTE(S):

• Tata Memorial Hospital, Mumbai
• AIIMS, New Delhi
• Royal College of Physicians, UK

Dr. Choudhary completed his MBBS from the Government Medical College, Nagpur in 2007 and MD in General Medicine from the prestigious All India Institute of Medical Sciences (AIIMS), New Delhi in 2011. He completed his DM in Medical Oncology from Tata Memorial Hospital, Mumbai in 2015. Later, in 2015, Dr. Choudhary obtained the European Certification in Medical Oncology and subsequently obtained the specialty certificate in Medical Oncology - MRCP (UK) in 2016.

In the field of clinical research, Dr. Choudhary has participated in many studies in the area of cancer. Also, he has been the principal investigator of various clinical trials.

With experience that spans over a decade, Dr. Choudhary has worked at some of the prestigious multi-specialty hospitals in India like American Oncology Institute Nagpur, HCG Cancer Centre Nagpur, Narayana Hospital Jaipur.

KDAH EXPERIENCE

Dr. Vaibhav Choudhary is working as a Consultant in the Department of Medical Oncology in the Cancer Centre at KDAH. He is responsible for the medical management of Cancer patients requiring Immunotherapy, Targeted therapy, and Chemotherapy.

Dr. Choudhary has participated in numerous national as well as international seminars and workshops. He has published several papers in various high-ranked medical journals and is a member of prestigious medical associations such as the American Society of Clinical Oncology, the European Society of Medical Oncology, and the Indian Society of Medical and Pediatric Oncology.He is a much sought after speaker at national and international oncology conferences.

Clinical Research Experience

• MD Thesis: ‘Acute Febrile Illness With Thrombocytopenia’ AIIMS New Delhi, 2008 to 2011
• DM Thesis: ‘A Retrospective Audit Of Clinical Characteristics, Treatment And Outcome Of Patients With Gestational Trophoblastic Neoplasia Treated At Tata Memorial Center From Jan 2009 To Dec 2012.’

Principal Investigator

• A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA) Study Code: D9100C00001
• ARL/CT/18/004 Phase: Bioequivalence study with pharmacokinetic endpoints under steady-state. Sponsor: NATCO Pharma. Ltd IP: 15 mg Trifluridine/6.14 mg Tipiracil and 20 mg Trifluridine/8.19 mg Tipiracil Tablet Regulatory Submission: USFDA.
• A Phase 1b/2 Open-label Study with Randomization in Phase 2 of IMU-131 HER2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction.
• A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician’s Choice Of Adjuvant Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer. Title: Safety and Efficacy of EribulinMesylate in Patients with Locally Advanced or Metastatic Breast Cancer: Results of a multicenter Phase IV study in India.
• Study Title: A prospective, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).
• Protocol Entitled: A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) with Reference Pertuzumab (Perjeta®, Genetech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer.
• A Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when given in combination with Paclitaxel in patients diagnosed with HER2 Positive Metastatic Breast Cancer.

Publications

• PDL1 expression testing in head and neck squamous cell carcinoma: Bridging the gap
• Review article: Status Of Cancer Research In India – Published in IACR 2015 Book
• Comprehensive Genomic Profiling In Breast Cancer- Is It Ready For Prime Time Use? Choudhary V, Gupta S.Current Breast Cancer Reports. June 2016, Volume 8, Issue 2, pp 53-59
• Bajpai J, Choudhary V (2016) Targeted Therapy Of Soft Tissue Sarcoma: There Is More than One Way To Skin A Cat! Chemo Open Access 5:216

PROFESSIONAL MEMBERSHIPS

• American Society of Clinical Oncology
• European Society of Medical Oncology
• Indian Society of Medical and Pediatric Oncology
• Indian Association of supportive care in Cancer